Table 1 Sociodemographic and clinical characteristics of participants and non-participants
|  | Participants (n = 100) | Non-participants (n = 110) | p-value†|
|---|---|---|---|
Age, mean years (SD) | 67 (11.4) | 69 (10.11) | ns |
Sex | Â | Â | ns |
Female | 17 (17%) | 22 (20%) | Â |
Male | 83 (83%) | 88 (80%) | Â |
Tumour site | Â | Â | Â |
Glottic | 72 (72%) | 61 (55%) | 0.0188 |
Supraglottic | 20 (20%) | 37 (34%) | 0.0382 |
Subglottic | 4 (4%) | 3 (3%) | ns |
Transglottic | 4 (4%) | 9 (8%) | ns |
Stage | Â | Â | Â |
0 | 3 (3%) | 2 (2%) | Â |
I | 57 (57%) | 43 (39%) | Â |
II | 22 (22%) | 24 (22%) | Â |
III | 9 (9%) | 17 (15%) | Â |
IV | 9 (9%) | 24 (22%) | 0.001 |
Karnofsky performance scale | Â | Â | Â |
100 | 60 (63%) | 34 (33%) | Â |
90 | 23 (24%) | 33 (31%) | Â |
80 | 8 (8%) | 20 (19%) | Â |
70 | 3 (3%) | 12 (11%) | Â |
60 | 0 (0%) | 1 (1%) | Â |
50 | 1 (1%) | 1 (1%) | Â |
40 | 0 (0%) | 4 (4%) | >0.001 |
Married/Cohabitant | 70 (70%) | 62 (56%) | ns |
Smokers | 50 (50%) | 70 (64%) | ns |
Loss of weight | 21 (21%) | 35 (32%) | ns |
Residual disease | 2 (2%) | 2 (2%) | ns |
Cardiovascular disease | 45 (45%) | 38 (35%) | ns |
Other malignancy | 8 (8%) | 11 (10%) | ns |